New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide ethanol hypromellose as 0.087 mg pigment suspension white + 0.087 mg pigment suspension yellow + 1.663 mg additional iron oxide yellow lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years. first-line treatment in postmenopausal women with advanced breast cancer advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.

Canada - English - Health Canada

sanis health inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Canada - English - Health Canada

sivem pharmaceuticals ulc - letrozole - tablet - 2.5mg - letrozole 2.5mg

Canada - English - Health Canada

fresenius kabi canada ltd - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Canada - English - Health Canada

pro doc limitee - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide hypromellose as 0.087 mg pigment suspension white + 0.087 mg pigment suspension yellow + 1.663 mg additional iron oxide yellow lactose monohydrate macrogols magnesium stearate maize starch microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide - adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years. first-line treatment in postmenopausal women with advanced breast cancer advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.

Canada - English - Health Canada

taro pharmaceuticals inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Canada - English - Health Canada

meliapharm inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Canada - English - Health Canada

actavis pharma company - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 sodium starch glycolate